Willmark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 10-12-2024
- Paid Up Capital ₹ 0.20 M
as on 10-12-2024
- Company Age 39 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.67 Cr
as on 10-12-2024
- Revenue -12.76%
(FY 2022)
- Profit -51.74%
(FY 2022)
- Ebitda -19.97%
(FY 2022)
- Net Worth 10.51%
(FY 2022)
- Total Assets -0.64%
(FY 2022)
About Willmark Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹4.67 Cr.
Rajan Bhardwaj and Rajiv Bhardwaj serve as directors at the Company.
- CIN/LLPIN
U24232PB1985PTC006176
- Company No.
006176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 1985
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationPunjab, Punjab
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Willmark Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Bhardwaj  | Managing Director | 14-Mar-1985 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajan Bhardwaj | Director | 01-Apr-1998 | Current |
Financial Performance of Willmark Pharmaceuticals.
Willmark Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 12.76% decrease. The company also saw a substantial fall in profitability, with a 51.74% decrease in profit. The company's net worth Soared by an impressive increase of 10.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Willmark Pharmaceuticals?
Unlock access to Willmark Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 26 Apr 2024 | ₹0.32 M | Open |
Hdfc Bank Limited Creation Date: 25 Oct 2023 | ₹0.66 M | Open |
Hdfc Bank Limited Creation Date: 20 Jan 2021 | ₹1.21 M | Open |
How Many Employees Work at Willmark Pharmaceuticals?
Willmark Pharmaceuticals has a workforce of 15 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Willmark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Willmark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
